Evidence map›Paper›PMID 33009718›Full record

ArticlePharmacoepidemiology and drug safety2021

Patterns of anticonvulsant use and adverse drug events in older adults.

Lidia M V R Moura, Jason R Smith, Zhiyu Yan, Deborah Blacker, Lee H Schwamm, Joseph P Newhouse, Sonia Hernandez-Diaz, John Hsu

Abstract read
In one paragraph

Article in Pharmacoepidemiology and drug safety, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lidia M V R MouraDepartment of Neurology, Massachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0002-1191-1315
Jason R SmithDepartment of Neurology, Massachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0001-9764-5849
Zhiyu YanDepartment of Neurology, Massachusetts General Hospital, Boston, Massachusetts.
Deborah BlackerDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Lee H SchwammDepartment of Neurology, Massachusetts General Hospital, Boston, Massachusetts.
Joseph P NewhouseDepartment of Health Care Policy, Harvard Medical School, Boston, Massachusetts.
Sonia Hernandez-DiazDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.ORCID 0000-0003-1458-7642
John HsuDepartment of Health Care Policy, Harvard Medical School, Boston, Massachusetts.

Funding

Alzheimer's Disease Genetics ConsortiumU01AG032984 · NIA · UNIVERSITY OF PENNSYLVANIA · PI SCHELLENBERG, GERARD DAVID · 2009 to 2024
$60.4M
Vascular factors, physical activity, and inflammation as modulators of neurodegenerative and cognitive trajectories (Project 2)P01AG036694 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Hyun-Sik Yang · 2010 to 2026
$50.2M
Tradeoffs in the Design of Public Long-Term Care BenefitsP01AG032952 · NIA · HARVARD MEDICAL SCHOOL · PI Leila S. Agha · 2009 to 2026
$39.0M
Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Christine S Ritchie · 2019 to 2026
$36.5M
VCID Biomarkers Coordinating CenterU24NS100591 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI Steven M Greenberg · 2016 to 2026
$19.8M
Randomized controlled trial of enhanced coordinated specialty care (CSC 2.0)P50MH115846 · NIMH · MCLEAN HOSPITAL · PI Dost Ongur · 2019 to 2026
$16.9M
Harnessing Diverse Bioinformatic Approaches To Repurpose Drugs For Alzheimers Disease And Related DementiasR01AG058063 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI MARK W ALBERS, PETER Karl SORGER · 2018 to 2026
$7.8M
VITAL-DEP: Depression Endpoint Prevention in the VITamin D and OmegA-3 TriaLR01MH091448 · NIMH · BRIGHAM AND WOMEN'S HOSPITAL · PI OKEREKE, OLIVIA IFEOMA · 2010 to 2019
$6.5M
COVID-19 and Acute Medical Care: Impact on Dementia PatientsR01AG062282 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI HSU, JOHN · 2018 to 2022
$4.5M
Neural and cognitive changes associated with mindfulness training in older adultsR01AG048351 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI DICKERSON, BRADFORD C, LAZAR, SARA W · 2015 to 2019
$4.0M
Fixed Dose Intervention Trial of New England Enhancing Survival in SMI PatientsR01MH104560 · NIMH · MCLEAN HOSPITAL · PI HSU, JOHN, ONGUR, DOST · 2014 to 2017
$3.0M
Long-term Impact of Fertility Treatment StudyR01HD088393 · NICHD · MASSACHUSETTS GENERAL HOSPITAL · PI HERNAN, MIGUEL, HERNANDEZ-DIAZ, SONIA · 2017 to 2022
$2.9M
NIA NIH HHS K08 AG053380NIA NIH HHS P01 AG032952NIA NIH HHS P01 AG036694NIA NIH HHS P30 AG062421NIA NIH HHS R01 AG048351NIA NIH HHS R01 AG058063NIA NIH HHS R01 AG062282NIA NIH HHS T32 AG051108NIA NIH HHS U01 AG032984NICHD NIH HHS R01 HD088393NIH HHS 1K08AG053380-01A1NIMH NIH HHS P50 MH115846NIMH NIH HHS R01 MH091448NIMH NIH HHS R01 MH104560NINDS NIH HHS U24 NS100591
6 · The paper itself

Abstract

purposeTo examine indications for, duration of use, and rate of adverse drug events (ADE) attributable to anticonvulsant initiation, as adjudicated by expert review of electronic health records (EHR) of older adults.

methodsWe identified a cohort of community dwelling Medicare beneficiaries with linked EHR (aged 65+, continuously enrolled with a large health system/until death between 2012 and 2014, n = 20 945) and drew a stratified EHR review sample (n = 1534). An expert reviewed all records to adjudicate anticonvulsant use, years of use, indication for use, and evidence of ADEs attributable to anticonvulsant initiation. After excluding patients with insufficient EHR data (n = 37; 2%), we reconstructed the cohort using inverse probability weights to resemble the original cohort of eligible beneficiaries (n = 20 380). Among incident users of a single anticonvulsant, we estimated the rate of ADEs and described the type and severity of ADEs.

resultsOverall, 12% (n = 2469) of eligible beneficiaries used at least one anticonvulsant in the 2012 to 2014 period (4% [n = 757] incident users, 8% [n = 1712] prevalent users). Incident users were most frequently prescribed gabapentin (n = 461/757, 61%), benzodiazepines (n = 122/757, 16%), and levetiracetam (n = 74/757, 10%); the most common indication was pain relief (n = 214; 28%) followed by epilepsy (n = 53; 7%). Among incident users, the overall ADE rate was 10/100 person-years (95% CI 4-20/100 person-years), of which 29% (n = 28/97) were life threatening (eg, somnolence). Most ADEs among incident monotherapy users were nervous system related (68%, n = 66/97).

conclusionMany older adult community dwelling traditional Medicare beneficiaries had clinically significant ADEs likely attributable to the initiation of anticonvulsant therapy, which was begun for a range of indications.

Indexed as

Drug-Related Side Effects and Adverse ReactionsEpilepsyAgedAnticonvulsantsCohort StudiesHumansMedicareUnited StatesAnticonvulsantsAged, anticonvulsants, neurology, outcome assessment, patient safety

Identifiers

PMID33009718
PMCPMC7849867

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.